Ontology type: schema:ScholarlyArticle
2021-10-13
AUTHORSAndrea Bever, Jackie Manthorne, Tissa Rahim, Layla Moumin, Shelagh M. Szabo
ABSTRACTBackgroundIn lung cancer trials, overall survival is a well-validated and widely used endpoint; yet, in the context of adjuvant or curative intent treatments, disease-free survival (DFS) may be a better indicator of transformative patient outcomes. Although use of DFS is growing, patient perceptions of its relevance have not been established.ObjectiveWe aimed to understand the importance of DFS as a trial endpoint, from the perspective of survivors of lung cancer.MethodsWeb-based qualitative interviews were conducted with Canadian survivors of stage Ib–IIIa lung cancer. Participants described their experiences of cancer diagnosis and treatment, including their treatment goals and priorities. Participants then provided their perspectives on DFS and overall survival, and how well each aligned with their treatment priorities. Thematic analysis was used to explore patterns in responses.ResultsAmong the 18 participants (mean age, 64 years), 83% were female, most (89%) had received surgery, and 56% received chemotherapy. Most participants viewed DFS as an intrinsically meaningful treatment outcome, for reasons such as alignment with treatment goals, and the perception that DFS would help maintain a high quality of life. One individual was interested in DFS only as a potential surrogate for overall survival. Participants desired access to new treatments that improve DFS and emphasized this within the context of promoting patient agency in treatment decision making.ConclusionsThese findings suggest DFS is a meaningful endpoint from the perspective of survivors of lung cancer; and may help inform decisions regarding regulatory approval and reimbursement of new treatments based on DFS data. More... »
PAGES1-10
http://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w
DOIhttp://dx.doi.org/10.1007/s40271-021-00552-w
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1141848861
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34643935
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Broadstreet HEOR, Vancouver, BC, Canada",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Broadstreet HEOR, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Bever",
"givenName": "Andrea",
"id": "sg:person.016336044014.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016336044014.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Canadian Cancer Survivor Network, Ottawa, ON, Canada",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Canadian Cancer Survivor Network, Ottawa, ON, Canada"
],
"type": "Organization"
},
"familyName": "Manthorne",
"givenName": "Jackie",
"id": "sg:person.07632772614.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07632772614.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Broadstreet HEOR, Vancouver, BC, Canada",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Broadstreet HEOR, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Rahim",
"givenName": "Tissa",
"id": "sg:person.012246573573.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012246573573.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Canadian Cancer Survivor Network, Ottawa, ON, Canada",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Canadian Cancer Survivor Network, Ottawa, ON, Canada"
],
"type": "Organization"
},
"familyName": "Moumin",
"givenName": "Layla",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Broadstreet HEOR, Vancouver, BC, Canada",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Broadstreet HEOR, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Szabo",
"givenName": "Shelagh M.",
"id": "sg:person.0750556372.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750556372.03"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/s41392-019-0099-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1123443998",
"https://doi.org/10.1038/s41392-019-0099-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10508-012-0016-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035291402",
"https://doi.org/10.1007/s10508-012-0016-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf02596485",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050744497",
"https://doi.org/10.1007/bf02596485"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s40271-021-00528-w",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1138780781",
"https://doi.org/10.1007/s40271-021-00528-w"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10198-014-0622-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050041525",
"https://doi.org/10.1007/s10198-014-0622-4"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-10-13",
"datePublishedReg": "2021-10-13",
"description": "BackgroundIn lung cancer trials, overall survival is a well-validated and widely used endpoint; yet, in the context of adjuvant or curative intent treatments, disease-free survival (DFS) may be a better indicator of transformative patient outcomes. Although use of DFS is growing, patient perceptions of its relevance have not been established.ObjectiveWe aimed to understand the importance of DFS as a trial endpoint, from the perspective of survivors of lung cancer.MethodsWeb-based qualitative interviews were conducted with Canadian survivors of stage Ib\u2013IIIa lung cancer. Participants described their experiences of cancer diagnosis and treatment, including their treatment goals and priorities. Participants then provided their perspectives on DFS and overall survival, and how well each aligned with their treatment priorities. Thematic analysis was used to explore patterns in responses.ResultsAmong the 18 participants (mean age, 64 years), 83% were female, most (89%) had received surgery, and 56% received chemotherapy. Most participants viewed DFS as an intrinsically meaningful treatment outcome, for reasons such as alignment with treatment goals, and the perception that DFS would help maintain a high quality of life. One individual was interested in DFS only as a potential surrogate for overall survival. Participants desired access to new treatments that improve DFS and emphasized this within the context of promoting patient agency in treatment decision making.ConclusionsThese findings suggest DFS is a meaningful endpoint from the perspective of survivors of lung cancer; and may help inform decisions regarding regulatory approval and reimbursement of new treatments based on DFS data.",
"genre": "article",
"id": "sg:pub.10.1007/s40271-021-00552-w",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1038760",
"issn": [
"1178-1653",
"1178-1661"
],
"name": "The Patient - Patient-Centered Outcomes Research",
"publisher": "Springer Nature",
"type": "Periodical"
}
],
"keywords": [
"disease-free survival",
"lung cancer",
"overall survival",
"trial endpoints",
"treatment goals",
"Canadian survivors",
"new treatments",
"meaningful treatment outcomes",
"curative-intent treatment",
"perspectives of survivors",
"lung cancer trials",
"clinical trial endpoints",
"intent treatment",
"patients' perceptions",
"cancer trials",
"patient outcomes",
"treatment outcomes",
"treatment decisions",
"treatment priorities",
"meaningful endpoints",
"cancer",
"ConclusionsThese findings",
"DFS data",
"survivors",
"cancer diagnosis",
"endpoint",
"survival",
"Most participants",
"patient agency",
"regulatory approval",
"treatment",
"potential surrogate",
"participants",
"outcomes",
"qualitative study",
"thematic analysis",
"qualitative interviews",
"chemotherapy",
"surgery",
"ResultsAmong",
"diagnosis",
"ObjectiveWe",
"trials",
"reimbursement",
"MethodsWeb",
"good indicator",
"approval",
"findings",
"individuals",
"response",
"surrogate",
"study",
"life",
"perception",
"interviews",
"priority",
"relevance",
"importance",
"experience",
"use",
"indicators",
"goal",
"patterns",
"access",
"data",
"quality",
"decisions",
"high quality",
"reasons",
"analysis",
"perspective",
"context",
"agencies"
],
"name": "The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer",
"pagination": "1-10",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1141848861"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s40271-021-00552-w"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34643935"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s40271-021-00552-w",
"https://app.dimensions.ai/details/publication/pub.1141848861"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:29",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_895.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s40271-021-00552-w"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'
This table displays all metadata directly associated to this object as RDF triples.
178 TRIPLES
22 PREDICATES
102 URIs
89 LITERALS
5 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s40271-021-00552-w | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1112 |
3 | ″ | schema:author | Ne14c87317d8246bcacf122c5bb401233 |
4 | ″ | schema:citation | sg:pub.10.1007/bf02596485 |
5 | ″ | ″ | sg:pub.10.1007/s10198-014-0622-4 |
6 | ″ | ″ | sg:pub.10.1007/s10508-012-0016-6 |
7 | ″ | ″ | sg:pub.10.1007/s40271-021-00528-w |
8 | ″ | ″ | sg:pub.10.1038/s41392-019-0099-9 |
9 | ″ | schema:datePublished | 2021-10-13 |
10 | ″ | schema:datePublishedReg | 2021-10-13 |
11 | ″ | schema:description | BackgroundIn lung cancer trials, overall survival is a well-validated and widely used endpoint; yet, in the context of adjuvant or curative intent treatments, disease-free survival (DFS) may be a better indicator of transformative patient outcomes. Although use of DFS is growing, patient perceptions of its relevance have not been established.ObjectiveWe aimed to understand the importance of DFS as a trial endpoint, from the perspective of survivors of lung cancer.MethodsWeb-based qualitative interviews were conducted with Canadian survivors of stage Ib–IIIa lung cancer. Participants described their experiences of cancer diagnosis and treatment, including their treatment goals and priorities. Participants then provided their perspectives on DFS and overall survival, and how well each aligned with their treatment priorities. Thematic analysis was used to explore patterns in responses.ResultsAmong the 18 participants (mean age, 64 years), 83% were female, most (89%) had received surgery, and 56% received chemotherapy. Most participants viewed DFS as an intrinsically meaningful treatment outcome, for reasons such as alignment with treatment goals, and the perception that DFS would help maintain a high quality of life. One individual was interested in DFS only as a potential surrogate for overall survival. Participants desired access to new treatments that improve DFS and emphasized this within the context of promoting patient agency in treatment decision making.ConclusionsThese findings suggest DFS is a meaningful endpoint from the perspective of survivors of lung cancer; and may help inform decisions regarding regulatory approval and reimbursement of new treatments based on DFS data. |
12 | ″ | schema:genre | article |
13 | ″ | schema:inLanguage | en |
14 | ″ | schema:isAccessibleForFree | false |
15 | ″ | schema:isPartOf | sg:journal.1038760 |
16 | ″ | schema:keywords | Canadian survivors |
17 | ″ | ″ | ConclusionsThese findings |
18 | ″ | ″ | DFS data |
19 | ″ | ″ | MethodsWeb |
20 | ″ | ″ | Most participants |
21 | ″ | ″ | ObjectiveWe |
22 | ″ | ″ | ResultsAmong |
23 | ″ | ″ | access |
24 | ″ | ″ | agencies |
25 | ″ | ″ | analysis |
26 | ″ | ″ | approval |
27 | ″ | ″ | cancer |
28 | ″ | ″ | cancer diagnosis |
29 | ″ | ″ | cancer trials |
30 | ″ | ″ | chemotherapy |
31 | ″ | ″ | clinical trial endpoints |
32 | ″ | ″ | context |
33 | ″ | ″ | curative-intent treatment |
34 | ″ | ″ | data |
35 | ″ | ″ | decisions |
36 | ″ | ″ | diagnosis |
37 | ″ | ″ | disease-free survival |
38 | ″ | ″ | endpoint |
39 | ″ | ″ | experience |
40 | ″ | ″ | findings |
41 | ″ | ″ | goal |
42 | ″ | ″ | good indicator |
43 | ″ | ″ | high quality |
44 | ″ | ″ | importance |
45 | ″ | ″ | indicators |
46 | ″ | ″ | individuals |
47 | ″ | ″ | intent treatment |
48 | ″ | ″ | interviews |
49 | ″ | ″ | life |
50 | ″ | ″ | lung cancer |
51 | ″ | ″ | lung cancer trials |
52 | ″ | ″ | meaningful endpoints |
53 | ″ | ″ | meaningful treatment outcomes |
54 | ″ | ″ | new treatments |
55 | ″ | ″ | outcomes |
56 | ″ | ″ | overall survival |
57 | ″ | ″ | participants |
58 | ″ | ″ | patient agency |
59 | ″ | ″ | patient outcomes |
60 | ″ | ″ | patients' perceptions |
61 | ″ | ″ | patterns |
62 | ″ | ″ | perception |
63 | ″ | ″ | perspective |
64 | ″ | ″ | perspectives of survivors |
65 | ″ | ″ | potential surrogate |
66 | ″ | ″ | priority |
67 | ″ | ″ | qualitative interviews |
68 | ″ | ″ | qualitative study |
69 | ″ | ″ | quality |
70 | ″ | ″ | reasons |
71 | ″ | ″ | regulatory approval |
72 | ″ | ″ | reimbursement |
73 | ″ | ″ | relevance |
74 | ″ | ″ | response |
75 | ″ | ″ | study |
76 | ″ | ″ | surgery |
77 | ″ | ″ | surrogate |
78 | ″ | ″ | survival |
79 | ″ | ″ | survivors |
80 | ″ | ″ | thematic analysis |
81 | ″ | ″ | treatment |
82 | ″ | ″ | treatment decisions |
83 | ″ | ″ | treatment goals |
84 | ″ | ″ | treatment outcomes |
85 | ″ | ″ | treatment priorities |
86 | ″ | ″ | trial endpoints |
87 | ″ | ″ | trials |
88 | ″ | ″ | use |
89 | ″ | schema:name | The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer |
90 | ″ | schema:pagination | 1-10 |
91 | ″ | schema:productId | N9afedbb4f2cc4f1f8f919581e936a040 |
92 | ″ | ″ | Na586d4d08a1e4a9faa03ebff82ffdb6d |
93 | ″ | ″ | Nc16f0c7eae7b46d4b7f63dc360cfd420 |
94 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1141848861 |
95 | ″ | ″ | https://doi.org/10.1007/s40271-021-00552-w |
96 | ″ | schema:sdDatePublished | 2022-05-10T10:29 |
97 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
98 | ″ | schema:sdPublisher | Nc65ebbcf37ad4cbdaaa7a1de70db8fdd |
99 | ″ | schema:url | https://doi.org/10.1007/s40271-021-00552-w |
100 | ″ | sgo:license | sg:explorer/license/ |
101 | ″ | sgo:sdDataset | articles |
102 | ″ | rdf:type | schema:ScholarlyArticle |
103 | N0ef9dcc4cc5d42db9f1c188a622597e1 | rdf:first | sg:person.07632772614.46 |
104 | ″ | rdf:rest | Nb88af9402c194d1aa017e5064fd8e189 |
105 | N9afedbb4f2cc4f1f8f919581e936a040 | schema:name | doi |
106 | ″ | schema:value | 10.1007/s40271-021-00552-w |
107 | ″ | rdf:type | schema:PropertyValue |
108 | Na3510ac3846d4c4eabf57dbe091dca52 | schema:affiliation | grid-institutes:None |
109 | ″ | schema:familyName | Moumin |
110 | ″ | schema:givenName | Layla |
111 | ″ | rdf:type | schema:Person |
112 | Na586d4d08a1e4a9faa03ebff82ffdb6d | schema:name | pubmed_id |
113 | ″ | schema:value | 34643935 |
114 | ″ | rdf:type | schema:PropertyValue |
115 | Nb88af9402c194d1aa017e5064fd8e189 | rdf:first | sg:person.012246573573.48 |
116 | ″ | rdf:rest | Nd580e37d78e541ff990051910cf8b2e8 |
117 | Nc16f0c7eae7b46d4b7f63dc360cfd420 | schema:name | dimensions_id |
118 | ″ | schema:value | pub.1141848861 |
119 | ″ | rdf:type | schema:PropertyValue |
120 | Nc65ebbcf37ad4cbdaaa7a1de70db8fdd | schema:name | Springer Nature - SN SciGraph project |
121 | ″ | rdf:type | schema:Organization |
122 | Nd3b688fe3eb44815b07fb9cc3206cdbd | rdf:first | sg:person.0750556372.03 |
123 | ″ | rdf:rest | rdf:nil |
124 | Nd580e37d78e541ff990051910cf8b2e8 | rdf:first | Na3510ac3846d4c4eabf57dbe091dca52 |
125 | ″ | rdf:rest | Nd3b688fe3eb44815b07fb9cc3206cdbd |
126 | Ne14c87317d8246bcacf122c5bb401233 | rdf:first | sg:person.016336044014.46 |
127 | ″ | rdf:rest | N0ef9dcc4cc5d42db9f1c188a622597e1 |
128 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
129 | ″ | schema:name | Medical and Health Sciences |
130 | ″ | rdf:type | schema:DefinedTerm |
131 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
132 | ″ | schema:name | Oncology and Carcinogenesis |
133 | ″ | rdf:type | schema:DefinedTerm |
134 | sg:journal.1038760 | schema:issn | 1178-1653 |
135 | ″ | ″ | 1178-1661 |
136 | ″ | schema:name | The Patient - Patient-Centered Outcomes Research |
137 | ″ | schema:publisher | Springer Nature |
138 | ″ | rdf:type | schema:Periodical |
139 | sg:person.012246573573.48 | schema:affiliation | grid-institutes:None |
140 | ″ | schema:familyName | Rahim |
141 | ″ | schema:givenName | Tissa |
142 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012246573573.48 |
143 | ″ | rdf:type | schema:Person |
144 | sg:person.016336044014.46 | schema:affiliation | grid-institutes:None |
145 | ″ | schema:familyName | Bever |
146 | ″ | schema:givenName | Andrea |
147 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016336044014.46 |
148 | ″ | rdf:type | schema:Person |
149 | sg:person.0750556372.03 | schema:affiliation | grid-institutes:None |
150 | ″ | schema:familyName | Szabo |
151 | ″ | schema:givenName | Shelagh M. |
152 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750556372.03 |
153 | ″ | rdf:type | schema:Person |
154 | sg:person.07632772614.46 | schema:affiliation | grid-institutes:None |
155 | ″ | schema:familyName | Manthorne |
156 | ″ | schema:givenName | Jackie |
157 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07632772614.46 |
158 | ″ | rdf:type | schema:Person |
159 | sg:pub.10.1007/bf02596485 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1050744497 |
160 | ″ | ″ | https://doi.org/10.1007/bf02596485 |
161 | ″ | rdf:type | schema:CreativeWork |
162 | sg:pub.10.1007/s10198-014-0622-4 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1050041525 |
163 | ″ | ″ | https://doi.org/10.1007/s10198-014-0622-4 |
164 | ″ | rdf:type | schema:CreativeWork |
165 | sg:pub.10.1007/s10508-012-0016-6 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1035291402 |
166 | ″ | ″ | https://doi.org/10.1007/s10508-012-0016-6 |
167 | ″ | rdf:type | schema:CreativeWork |
168 | sg:pub.10.1007/s40271-021-00528-w | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1138780781 |
169 | ″ | ″ | https://doi.org/10.1007/s40271-021-00528-w |
170 | ″ | rdf:type | schema:CreativeWork |
171 | sg:pub.10.1038/s41392-019-0099-9 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1123443998 |
172 | ″ | ″ | https://doi.org/10.1038/s41392-019-0099-9 |
173 | ″ | rdf:type | schema:CreativeWork |
174 | grid-institutes:None | schema:alternateName | Broadstreet HEOR, Vancouver, BC, Canada |
175 | ″ | ″ | Canadian Cancer Survivor Network, Ottawa, ON, Canada |
176 | ″ | schema:name | Broadstreet HEOR, Vancouver, BC, Canada |
177 | ″ | ″ | Canadian Cancer Survivor Network, Ottawa, ON, Canada |
178 | ″ | rdf:type | schema:Organization |